Abstract: Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I.

Abstract: The instant invention provides compositions containing as active agents paromomycin in combination with gentamicin. When given in combination, the compositions appear much more effective than when given alone. Furthermore, the compositions of the invention were found to be effective against several species of Leishmania that were not effectively inhibited by the prior art compositions.

Abstract: A novel composition comprising Invaplex from gram-negative bacteria is described and is effective as a vaccine against gram-negative bacterial infection.

Abstract: This invention relates to the treatment of antibiotic-resistant infections, including particularly infections caused by bacteria, Mycobacteria and fungi. A preferred group of compositions of the invention contain as active agents compounds containing pyridyl, quinolyl or benzoquinolyl ring systems substituted on the nitrogen-containing ring at the carbon opposite the nitrogen by a carbon bound to an oxygen which is also bound to a nitrogen through a saturated carbon or carbon chain, or, in the case of the pyridyl ring system, the substituent at the 4 position of the pyridyl ring may be an alkyl which may be substituted with halo, hydroxy, alkoxy, amino or alkylamino.

Abstract: This invention relates to compounds of the general formula: wherein A is a aromatic hydrocarbon ring system and R1 is a carbon bound directly to an oxygen and is also bound to a nitrogen through a saturated carbon and wherein at least one of R2, R3 and R4 is an electron-rich substituent. The active agents are useful for treating patients suffering from infections including gram positive organisms, such as streptococcus, staphylococcus, anthracis, gram negative bacteria such as neisseria species, yeasts and mycobacterium. They are effective against strains which have shown resistance to other antimicrobial agents.

Abstract: A combined nasopharyngeal airway and pulse oximeter sensor capable of monitoring the posterior pharynx, posterior soft palate or nasal mucosa is disclosed. The nasopharyngeal airway includes a thickened wall section over approximately one-third of its circumference. Pulse oximeter sensor elements may be embedded in the airway. The pulse oximeter sensor elements may include a light source, which preferably emits light at wavelengths around 660 nm (red) and around 940 nm (near infrared), and a light detector. The pulse oximeter sensor elements may be connected to a pulse oximeter monitor (spectrophotometer) or other external device for analysis.

Abstract: In this application is described a method for overcoming alphavirus vaccine interference in alphavirus-immune subjects by administration of a second alphavirus vaccine which is altered such that it is not accessible to interfering antibodies. Examples of such alterations are described as well as evidence showing that alphavirus interference likely results from the binding of interfering antibodies to viral proteins expressed on infected cells thereby causing lysis of infected cells.

Abstract: cDNAs coding for an infectious Western Equine Encephalitis virus (WEE) and infectious Venezuelan Equine Encephalitis virus variant IE (VEE IE) are disclosed in addition to cDNA coding for the structural proteins of Venezuelan Equine Encephalitis virus variant IIIA (VEE IIIA). Novel attenuating mutations of WEE and VEE IE and their uses are described. Also disclosed are attenuated chimearic alphaviruses and their uses.

Abstract: A method for taking reflectance oximeter readings within the nasal cavity and oral cavity and down through the posterior pharynx. The method utilizes a reflectance pulse oximeter sensor that preferably is resistant to bodily fluids to contact one of these capillary beds for the taking of readings and then forwarding of these readings to an oximeter for display. The method includes inserting a reflectance pulse oximeter sensor into a cavity within a subject's skull and contacting a capillary bed disposed in the cavity with the reflectance pulse oximeter sensor.

Abstract: Particle mediated immunization of tick-borne flavivirus genes confers homologous and heterologous protection against tick borne encephalitis.

Abstract: An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models.

Abstract: A combined oropharyngeal airway/bite block is disclosed having pulse oximeter sensor elements capable of monitoring the posterior pharynx, the soft palate, the hard palate, and the buccal surface. The oropharyngeal airway portion has a thickened wall to house the pulse oximeter sensor elements and provide sufficient material to form grooves in the distal end. The grooves are utilized when the invention is turned on its side to act as a bite block with the grooves engaging the teeth of the patient. The pulse oximeter sensor elements include a light source, which emits light at wavelengths of about 660 nm and about 940 nm, and a light detector. The pulse oximeter sensor elements are in communication with a spectrophotometer for analysis.

Abstract: This invention is a protective covering to protect off-the-shelf disposable pulse oximeter sensors from bodily or surgical fluids. The protective covering will envelop and encase the inserted pulse oximeter sensor up to a point on the connection cable extending from the pulse oximeter sensor. The protective covering is a polypropylene, rubber, or similar material, which preferably is tapered from the large width at the entrance to the narrower width at the blind end. The protective covering is bilaminar in nature to contain a substantially rectangular pulse oximeter.

Abstract: Highly conserved polypeptide sequences derived from gp41 and gp120, preferably from eleven to twenty-one amino acids in length, are joined (for example, via DNA recombinant techniques) to a non-HIV protein or polypeptide sequence comprising an amino-acid sequence not naturally encoded by the HIV genome, thereby forming a fusion protein. Such fusion proteins possess attributes that make them suitable for use in the diagnosis, treatment and prevention of HIV infection.

Abstract: Invaplex, a novel composition comprising invasin proteins and LPS from gram-negative bacteria is described as well as methods of using the novel composition as an adjuvant and a diagnostic tool.

Abstract: A system and a method for providing a determination of predicted cognitive performance of an individual based the time of day and on factors including sleep history based on activity data from an actigraph. The system and the method provide a numerical representation of the predicted cognitive performance. Both may be used to optimize the work schedule of the actigraph wearer to maximize the cognitive capacity during working hours.

Abstract: A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a non-steroidal, antiinflammatory drug over a duration from 24 hours to 2 months, comprising: a non-steroidal, antiinflammatory drug and a blend of biocompatible, biodegradable poly (lactide/glycolide).

Abstract: Nucleic acid-based methods for the detection of Cyclospora are disclosed, including PCR-based and hybridization-based techniques.

Abstract: A method of reducing brain damage resulting from seizures caused by an organophosphorus nerve agent includes administering to a patient a therapeutically effective amount of HU-211. The organophosphorus nerve agent may be GB (sarin), GD (soman), GA (tabun) or GF. The therapeutically effective amount of HU-211 is in the range of about 48 mg to about 200 mg per day.